Comparative cost-effectiveness of three strategies for guiding second-line erlotinib initiation in non small-cell lung cancer: a French prospective multicenter study (ERMETIC Project Part 3) Short title: Erlotinib cost-effectiveness analysis in second-line lung cancer therapy